Overview

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC
Treatments:
fludrocortisone acetate
Prednisone